Tacere's shRNA Drug for HCV Subject of $145M Pfizer Deal Jan. 8, 2008 By Trista Morrison Tacere Therapeutics Inc. teamed up with Pfizer Inc. to develop and commercialize TT-033, a preclinical hepatitis C drug consisting of three short-hairpin RNAs (shRNAs) delivered within an adeno-associated virus (AAV) protein coat. (BioWorld Today)Read More
RSS